A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Patients 13 Years or Older With Asthma (CONNECT1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03890666|
Recruitment Status : Not yet recruiting
First Posted : March 26, 2019
Last Update Posted : October 5, 2020
This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, DHP (Cloud solution), and dashboard, to optimize outcomes in patients at least 13 years of age or older with asthma.
The study will consist of a screening visit, a 12-week open-label treatment period, and a follow-up telephone call (2 weeks following treatment completion).
Patients with suboptimal asthma control will be enrolled in the study and randomized in a 1:1 ratio to 1 of 2 parallel groups stratified by investigational center: DS group patients utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard, and CC group patients who will be treated with their standard of care albuterol-administering rescue inhalers and will not use the DS during the treatment period.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Albuterol eMDPI DS Drug: albuterol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||330 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma|
|Estimated Study Start Date :||October 20, 2020|
|Estimated Primary Completion Date :||October 23, 2021|
|Estimated Study Completion Date :||October 23, 2021|
Experimental: Digital System (DS) Group
DS group patients utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard
Drug: Albuterol eMDPI DS
Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 4 component devices:
Active Comparator: Concurrent Control (CC) Group
CC group patients will be treated with their standard of care albuterol-administering rescue inhalers
Standard of care albuterol-administering rescue inhaler
- Meaningful improvement in Asthma Control Test (ACT) score [ Time Frame: Baseline & Week 12 ]Meaningful improvement is defined as either an ACT score greater than or equal to 20 at the end of the 12-week treatment period or an increase of at least 3 units on the ACT score from baseline to the end of the 12-week treatment period.
- Number of clinically driven interactions with study staff based on information from the dashboard [ Time Frame: 12 weeks ]
- Change in the mean weekly SABA usage for the DS group [ Time Frame: Baseline thru week 12 ]Short-acting beta2 agonists (SABA)
- Change in the number of SABA-free days for the DS group. [ Time Frame: Baseline thru week 12 ]
- Assessment of the DS (eMDPI, App and dashboard) acceptability and usability, utilizing the System Usability Scale (SUS) [ Time Frame: Week 12 ]
The SUS will be completed by the patients in the DS group, 18 years of age or older, and the investigational center personnel at the end of the study.
Score from 0 (negative) to 100 (positive).
- Assessment of patients' beliefs Brief about Medication Questionnaire (BMQ) [ Time Frame: Baseline & Week 12 ]Assessment made by both the DS and CC groups, patients 18 years of age or older, describing their behavioral profile
- Assessment of patients' beliefs and perceptions about their disease and treatment, utilizingthe Brief Illness Perception Questionnaire (BIPQ) [ Time Frame: Baseline & Week 12 ]Assessment made by both the DS and CC groups, patients 18 years of age or older, describing their behavioral profile
- Percentage of adverse events related to Albuterol eMDPI [ Time Frame: 12 weeks ]adverse event data, adverse device effect data
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03890666
|Contact: Teva U.S. Medical Information||1-888-483-8279||USMedInfo@tevapharm.com|
|Study Director:||Teva Medical Expert, MD||Teva Pharmaceuticals USA|